Latham Group, Inc. Announces Second Quarter 2025 Earnings Release and Conference Call Date

(NASDAQ:SWIM), LATHAM, N.Y., July 08, 2025 (GLOBE NEWSWIRE) — Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it will release financial results for the second quarter 2025 on Tuesday, August 5, 2025, after the close of the […]

LendingClub Schedules Second Quarter 2025 Earnings Release and Conference Call

LendingClub Corporation(NYSE: LC), which operates America's leading digital marketplace bank, announced that it will report earnings for the second quarter of 2025 after the market closes on Tuesday, July 29, 2025.LendingClub will host a conference call to discuss the second quarter 2025 financial results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the

Saratoga Investment Corp. Announces Fiscal First Quarter 2026 Financial Results

Saratoga Investment Corp. Announces Fiscal First Quarter 2026 Financial Results GlobeNewswire July 08, 2025 Reports 17.9% Increase in Adjusted NII Per Share and 0.9% Increase in NAV from Previous Quarter Quarterly ROE of 14.1% Generates LTM ROE of 9.3% and Beats the BDC Industry Average of 7.0% NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) —

Realty Income Announces 661st Consecutive Common Stock Monthly Dividend

Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced that it has declared its 661stconsecutive common stock monthly dividend. The dividend amount of$0.269per share, representing an annualized amount of$3.228per share, is payable on August 15, 2025 to stockholders of record as of August 1, 2025. https://mma.prnewswire.com/media/122541/Realty_Income_Logo.jpg About Realty Income Realty Income

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Tyra Biosciences, Inc.(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA. Details of

Adeia to Release Second Quarter 2025 Financial Results on August 5, 2025

Adeia to Release Second Quarter 2025 Financial Results on August 5, 2025 GlobeNewswire July 08, 2025 SAN JOSE, Calif., July 08, 2025 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) will announce its financial results for the second quarter ended June 30, 2025, on Tuesday, August 5, 2025, following the close of market. The company will

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering GlobeNewswire July 08, 2025 PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale

RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance GlobeNewswire July 08, 2025 ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) GlobeNewswire July 08, 2025 – SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies – – SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease

Indonesia’s Consumer Protection Agency and Elong Power Enter into Strategic Cooperation Agreement

Indonesia's Consumer Protection Agency and Elong Power Enter into Strategic Cooperation Agreement GlobeNewswire July 08, 2025 Beijing, China, July 08, 2025 (GLOBE NEWSWIRE) — Elong Power Holding Limited (“Elong Power” or the “Company”) (Nasdaq: ELPW), a Nasdaq-listed company engaged in both high-power battery and energy storage system sectors, today announced that it has entered into

Scroll to Top